Dec 18 (Reuters) - Mesoblast Ltd MSB.AX :
* DATA MONITORING COMMITTEE COMPLETES FINAL SCHEDULED REVIEW OF MESOBLAST'S PHASE 3 TRIAL OF REVASCOR IN ADVANCED CHRONIC HEART FAILURE
* MESOBLAST - INDEPENDENT DMC OVERSEEING PHASE 3 TRIAL OF REVASCOR FOR ADVANCED CHRONIC HEART FAILURE RECOMMENDED THAT TRIAL CONTINUE AS PLANNED
* MESOBLAST LTD - RESULTS FROM CO'S PHASE 3 TRIAL OF REVASCOR EXPECTED TO BE READ OUT BY MID-2020